Johnson & Johnson (JNJ)

$274.55 +3.44 (1.27%)
Market Cap 632.28B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.97
Forward PE 22.42
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 4,920,448
Avg Vol 8,159,524
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 96%
Beta 0.24
Analysts Strong Sell
Price Target $275.42

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Outcomes
Outcomes Aug. 19 at 7:14 PM
$IBRX $MRNA $PFE $JNJ ….‘lying through his teeth’ And now, immunocompromise, ‘turbo-cancers’ etc. etc. etc. Hey, BTW have you seen all those videos of elite athletes falling over?? 🙏🏻🙏🏻
1 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:44 PM
$JNJ no you didn’t, you’ve never owned any of them. Don’t lie you loser, just shut up and go away.
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:09 PM
$JNJ Nailed it!!! Any other predictions professor?
1 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:07 PM
$JNJ Bearish on everything except renewable energy? How’s that working out for you? $JNJ up 32% this year and 54% on the calendar year. Keep crushing it my guy!!!
1 · Reply
HydrogenH2
HydrogenH2 Aug. 19 at 5:34 PM
$JNJ But JNJ will need to pay down that $5B baby powder mess eventually... and some meds are going generics.. So a lot of goodies are "priced in already !!
0 · Reply
PolyhedronPartners
PolyhedronPartners Aug. 19 at 4:44 PM
$JNJ remains a diversified global healthcare leader across pharmaceuticals, medical technology, and consumer health products. AERT reaffirmed FY2027 revenue guidance of $80 million–$84 million and adjusted EBITDA guidance of $10 million–$12 million.
0 · Reply
Ryuk
Ryuk Aug. 19 at 4:32 PM
$JNJ Red by close. Trash. 💩
0 · Reply
Imr77
Imr77 Aug. 19 at 4:31 PM
$SLS if I was BP i would have buy this when still cheap. after readout and the value becomes vivid + sls009 it would get whole lot more expensive smh. $JNJ you are up
0 · Reply
CHARTBUSTER12
CHARTBUSTER12 Aug. 19 at 3:56 PM
$JNJ good morning JNJ as i have been predicting will be going higher in price in 2026. my friends strong company plus many good things are coming. my friends watching SLS ,JNJ and AMPG a undervalue company going up in price this month. have a blessed day
1 · Reply
WhizBuckley
WhizBuckley Aug. 19 at 3:51 PM
🚨 TACTICAL TRADE ALERT BRIEF — TONIGHT, 7:00 PM EASTERN The psychedelic sector just had the biggest two-week stretch in its history, and most retail traders have no idea it's happening. In the last 12 days alone: → $LLY agreed to pay up to $3.8B to acquire atai/Beckley — a full strategic buyout, not a partnership → $JNJ stepped in to lead an $85M round into Delix Therapeutics, with rights to negotiate for the entire company → $DFTX (formerly MindMed) delivered a clean Phase 3 win in generalized anxiety disorder and immediately drew a fresh Buy initiation from Bank of America $BAC → President Trump personally announced the federal government now has direct access to the University of Miami's foundational ibogaine research, fast-tracking veteran treatment access. I met with VA Secretary Collins March of 25 and pushed hard for them to accept this data. → $CMPS remains on schedule for its Q4 NDA submission with a National Priority Voucher already in hand Register below:
1 · Reply
Latest News on JNJ
Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

2026-08-17T10:16:04.000Z - 2 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 5 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 10, 2026, 4:27 PM EDT - 8 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

2026-08-07T19:33:43.000Z - 11 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

Aug 6, 2026, 6:23 PM EDT - 12 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

2026-08-06T10:48:29.000Z - 13 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

2026-08-05T18:48:12.000Z - 14 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

IBM KO

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 4:05 PM EDT - 14 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

2026-08-04T12:50:51.000Z - 15 days ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 4, 2026, 8:45 AM EDT - 15 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Johnson & Johnson Transcript: Investor update

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

2026-08-03T11:00:29.000Z - 16 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

Johnson & Johnson removed from US Conviction List at Goldman Sachs

2026-08-03T09:35:43.000Z - 16 days ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 17 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

2026-07-30T12:35:46.000Z - 20 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 6:13 PM EDT - 20 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:42 PM EDT - 20 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 20 days ago

Johnson & Johnson lowers 2026 profit forecast

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 5:28 PM EDT - 20 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 21 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 4:31 PM EDT - 21 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 22 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 1:03 AM EDT - 22 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 22 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 9:29 PM EDT - 22 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:47 PM EDT - 22 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 6:31 PM EDT - 22 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

Jul 27, 2026, 5:45 AM EDT - 23 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23, 2026, 8:30 AM EDT - 27 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 4:33 PM EDT - 27 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:21 AM EDT - 4 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jim Cramer says this old-school investing concept still wins — even in the AI boom

Jul 21, 2026, 6:30 PM EDT - 4 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

DePuy Synthes Acquires Expanding Innovations™

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 5 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 5 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 5 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 5 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 5 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 5 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 5 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 6 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 7 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 7 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Outcomes
Outcomes Aug. 19 at 7:14 PM
$IBRX $MRNA $PFE $JNJ ….‘lying through his teeth’ And now, immunocompromise, ‘turbo-cancers’ etc. etc. etc. Hey, BTW have you seen all those videos of elite athletes falling over?? 🙏🏻🙏🏻
1 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:44 PM
$JNJ no you didn’t, you’ve never owned any of them. Don’t lie you loser, just shut up and go away.
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:09 PM
$JNJ Nailed it!!! Any other predictions professor?
1 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Aug. 19 at 6:07 PM
$JNJ Bearish on everything except renewable energy? How’s that working out for you? $JNJ up 32% this year and 54% on the calendar year. Keep crushing it my guy!!!
1 · Reply
HydrogenH2
HydrogenH2 Aug. 19 at 5:34 PM
$JNJ But JNJ will need to pay down that $5B baby powder mess eventually... and some meds are going generics.. So a lot of goodies are "priced in already !!
0 · Reply
PolyhedronPartners
PolyhedronPartners Aug. 19 at 4:44 PM
$JNJ remains a diversified global healthcare leader across pharmaceuticals, medical technology, and consumer health products. AERT reaffirmed FY2027 revenue guidance of $80 million–$84 million and adjusted EBITDA guidance of $10 million–$12 million.
0 · Reply
Ryuk
Ryuk Aug. 19 at 4:32 PM
$JNJ Red by close. Trash. 💩
0 · Reply
Imr77
Imr77 Aug. 19 at 4:31 PM
$SLS if I was BP i would have buy this when still cheap. after readout and the value becomes vivid + sls009 it would get whole lot more expensive smh. $JNJ you are up
0 · Reply
CHARTBUSTER12
CHARTBUSTER12 Aug. 19 at 3:56 PM
$JNJ good morning JNJ as i have been predicting will be going higher in price in 2026. my friends strong company plus many good things are coming. my friends watching SLS ,JNJ and AMPG a undervalue company going up in price this month. have a blessed day
1 · Reply
WhizBuckley
WhizBuckley Aug. 19 at 3:51 PM
🚨 TACTICAL TRADE ALERT BRIEF — TONIGHT, 7:00 PM EASTERN The psychedelic sector just had the biggest two-week stretch in its history, and most retail traders have no idea it's happening. In the last 12 days alone: → $LLY agreed to pay up to $3.8B to acquire atai/Beckley — a full strategic buyout, not a partnership → $JNJ stepped in to lead an $85M round into Delix Therapeutics, with rights to negotiate for the entire company → $DFTX (formerly MindMed) delivered a clean Phase 3 win in generalized anxiety disorder and immediately drew a fresh Buy initiation from Bank of America $BAC → President Trump personally announced the federal government now has direct access to the University of Miami's foundational ibogaine research, fast-tracking veteran treatment access. I met with VA Secretary Collins March of 25 and pushed hard for them to accept this data. → $CMPS remains on schedule for its Q4 NDA submission with a National Priority Voucher already in hand Register below:
1 · Reply
Orchard
Orchard Aug. 19 at 3:40 PM
Insiders buying or selling leading up to this? You all know they know the real story and it looks like they were selling and NOT BUYING. So f you were really curing cancer wouldn’t you be mortgaging your house to add to your position? $MRNA Watch these guys dump their shrs now. I trust Strip Club $RICK over these Big Pharma guys who can’t keep asbestos out of baby powder and skin cancer causing chemicals out of SUN SCREENS $JNJ (I’m talking to you) $PFE Lipitor cholesterol scam
1 · Reply
PitaPierogi
PitaPierogi Aug. 19 at 3:28 PM
$PHIO maybe we'll slowly rise on $MRNA and $MRK news. phio will be the direct competition. At a fraction of the price. Maybe they'll buy them out. $LLY $JNJ
0 · Reply
Orchard
Orchard Aug. 19 at 2:54 PM
$MRNA Can’t trust this company in any way. This will be another “100% safe and effective scam”. Just like $LLY trying to take GLP-1 off the market like Reta that cost less than $100 per month to sell their $1000+ a month. Remove bad cooking oils from your diets. Look into ivermectin and other off patent drugs that have been out for decades. $RICK I trust strip club operators more than pharma CO’s $JNJ that couldn’t make sunscreen and baby power that doesn’t cause cancer.
0 · Reply
USAEquityResearch
USAEquityResearch Aug. 19 at 2:45 PM
$JNJ 📊 USAEquityResearch ▲ 274.54 (+1.27%) Trend: Bullish 📈 RSI (14): 79.8 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 274.45 Support: 254.41 20-MA: 261.45 | 50-MA: 253.61 Educational content only. Not financial advice.
0 · Reply
frb1985
frb1985 Aug. 19 at 2:22 PM
$JNJ rut rho. Is that a new all time high. LOL
0 · Reply
Estimize
Estimize Aug. 19 at 2:15 PM
Wall St is expecting 2.90 EPS for $JNJ Q3 [Reporting 10/20 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 19 at 2:01 PM
$JNJ printed a new 52-week high today
0 · Reply
Investor203
Investor203 Aug. 19 at 1:20 PM
$MRNA $MRK $JNJ who is buying $VNDA
0 · Reply
yellowstar16
yellowstar16 Aug. 19 at 12:14 PM
$JNJ Ride MRNA draft. Will lift whole sector today. Cancer cure is right up JnJ alley. This may be the start of something wonderful.
0 · Reply
Imr77
Imr77 Aug. 19 at 11:32 AM
$SLS $JNJ better hurry up with the offer😉 or you will be left behind by $MRK
0 · Reply
LorriPurdy207
LorriPurdy207 Aug. 19 at 9:13 AM
$JNJ $BE $KOLD $KHC Johnson & Johnson provides diversified healthcare exposure, Bloom Energy benefits from data-center power demand, KOLD provides leveraged inverse natural-gas exposure, and Kraft Heinz remains tied to consumer staples demand. I'm watching healthcare demand, power contracts, natural-gas prices, pricing, and volumes.
0 · Reply
DeanPresto849
DeanPresto849 Aug. 19 at 7:15 AM
$JNJ $BE $KOLD $KHC Johnson & Johnson provides diversified healthcare exposure, Bloom Energy benefits from data-center power demand, KOLD provides leveraged inverse natural-gas exposure, and Kraft Heinz remains tied to consumer staples demand. I'm watching healthcare demand, power contracts, natural-gas prices, pricing, and volumes.
0 · Reply